Pear to host panel discussion with leaders who are paving the way to provide patients access to prescription digital therapeutics for the treatment of substance use and opioid use disorders
Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced the company will host an educational Vision Session at the Rx and Illicit Drug Summit (Rx Summit), April 18-21 in Atlanta, GA. The Rx Summit is the largest annual gathering for global stakeholders to address the opioid and addiction epidemic and share best practices and strategies for prevention, treatment, and recovery.
“The US has seen an unprecedented increase in drug use and overdose deaths during the COVID-19 pandemic, exacerbated by challenges for people living in isolation or with few viable treatment resources available,” said Yuri Maricich, MD, MBA, Chief Medical Officer, Pear Therapeutics. “At this year’s Rx Summit, we look forward to discussing with our clinician panelists how PDTs can address health equity and health care disparities, potentially improve treatment outcomes, and expand access to proven treatment options for people living with addiction.
The Vision Session, titled “Recovery is in Your Hands: How Access to Digital Therapeutics Can Drive Outcomes” will feature a presentation and panel discussion including decision makers who are leading the way to provide access to PDTs. The session will highlight how PDTs for substance use disorder (SUD) and opioid use disorder (OUD) are working to improve access to care for patients, including underserved populations, explore clinical outcomes and real-world engagement data, and discuss how various organizations and key decision makers can pave the way with digital treatments to treat serious diseases.
Panel participants will include:
- Shawn Ryan, MD, MBA; President and Chief Medical Officer, BrightView Health
- Timothy Aungst, PharmD; Associate Professor at MCPHS University, Worcester, MA, and Clinical Pharmacist in home health care.
- Sonji Adams, LPCC, LCADC; Behavioral Health Coordinator, Mountain Comprehensive Health Corporation
- George Kitchens, RPh; CEO, Artia Solutions and Former Pharmacy Services Bureau Chief, FL Medicaid
Pear Therapeutics is the category creator and leader in PDTs, having developed the first and only FDA-authorized PDTs to treat SUD and OUD. PDTs are a new therapeutic class that uses software to treat serious disease. Like traditional medicines, PDTs are developed in a GMP-compliant environment, tested in randomized controlled trials to demonstrate safety and effectiveness, evaluated for authorization by regulators like FDA, and used under the supervision of a prescribing clinician. Unlike traditional medicines, PDTs are designed to collect real world data for use by prescribing clinicians and for population health management by payers and health systems.
To learn more about the Session, which will take place on Tuesday, April 19 at 8:00 ET in International Ballroom A-D, please visit www.rx-summit.com/agenda.
For more information on Pear’s PDTs for SUD and OUD, visit www.resetforrecovery.com.
For more such updates and perspectives around Digital Innovation, IoT, Data Infrastructure, AI & Cybersecurity, go to AI-Techpark.com.
